Analysis of individual pathway alterations showed a trend toward reduced benefit from TT across most pathways ( Supplementary Table S4 , available at https://doi.org/10.1016/j.esmoop.2024.104112 ).
← all excerpts
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).
1
—
—